Imperial Confidence in Concept: ICiC
Lead Research Organisation:
Imperial College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- Imperial College London (Lead Research Organisation)
- Cancer Research UK (Collaboration)
- Eberhard Karls University of Tübingen (Collaboration)
- Francis Crick Institute (Collaboration)
- European Federation For Colposcopy (Collaboration)
- ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST (Collaboration)
- National Center for Scientific and Technological Research (CNRST) (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- University of Bristol (Collaboration)
Publications
Agustín-Pavón C
(2016)
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice
in Molecular Neurodegeneration
Arbyn M
(2017)
Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.
in The Lancet. Oncology
Chronopoulos A
(2017)
Exosomes as a platform for 'liquid biopsy' in pancreatic cancer
in Convergent Science Physical Oncology
Cook J
(2019)
First Trimester Circulating MicroRNA Biomarkers Predictive of Subsequent Preterm Delivery and Cervical Shortening.
in Scientific reports
Dortet L
(2018)
Rapid detection of colistin resistance in Acinetobacter baumannii using MALDI-TOF-based lipidomics on intact bacteria.
in Scientific reports
Dortet L
(2020)
Optimization of the MALDIxin test for the rapid identification of colistin resistance in Klebsiella pneumoniae using MALDI-TOF MS.
in The Journal of antimicrobial chemotherapy
Dortet L
(2018)
Rapid detection and discrimination of chromosome- and MCR-plasmid-mediated resistance to polymyxins by MALDI-TOF MS in Escherichia coli: the MALDIxin test.
in The Journal of antimicrobial chemotherapy
Furniss R
(2019)
Detection of Colistin Resistance in Escherichia coli by Use of the MALDI Biotyper Sirius Mass Spectrometry System
in Journal of Clinical Microbiology
Goya Grocin A
(2019)
Whole Proteome Profiling of N-Myristoyltransferase Activity and Inhibition Using Sortase A.
in Molecular & cellular proteomics : MCP
Guedán A
(2017)
Investigation of the Role of Protein Kinase D in Human Rhinovirus Replication.
in Journal of virology
| Description | STEM for Britain 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Although there is no immediate change in any health policy, the research presented in the House of Commons by Antonios Chronopoulos entails the development of low-cost, portable microfluidic chips that leverage cutting-edge acoustic-based microfluidic technology and nanomaterials for non-invasive (blood-based) early detection of pancreatic cancer, thus obviating the need for invasive tissue biopsies. |
| Description | (ExoSonic) - A microfluidic chip for non-invasive, early detection of pancreatic cancer - liquid biopsy |
| Amount | € 149,997 (EUR) |
| Funding ID | 780360 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 02/2018 |
| End | 07/2019 |
| Description | Confidence in Concept |
| Amount | £944,000 (GBP) |
| Funding ID | MC_PC_17162 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Confidence in Concept |
| Amount | £840,000 (GBP) |
| Funding ID | MC_PC_16046 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | Doctoral training centre in Neurotechnology |
| Amount | £0 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2021 |
| Description | ICiC 4 - Baldwin - Innovate UK Investment accelerator |
| Amount | £149,475 (GBP) |
| Funding ID | 582222 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2018 |
| Description | ICiC 4 - Choi - Bioengineering-Industry funding scheme Studentship |
| Amount | £50,000 (GBP) |
| Organisation | Bracco Group |
| Sector | Private |
| Country | Italy |
| Start | 01/2019 |
| End | 12/2021 |
| Description | ICiC 4 - Choi - Imperial-ICR Cancer Research UK Centre of Excellence |
| Amount | £165,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | ICiC 4 - Choi - The Cure Starts Now |
| Amount | $100,496 (USD) |
| Organisation | The Cure Starts Now |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 01/2019 |
| End | 12/2019 |
| Description | ICiC 4 - Choi - The Republic of Turkey Ministry of National Education PhD Studentship |
| Amount | £165,000 (GBP) |
| Organisation | Government of Turkey |
| Department | Ministry of National Education |
| Sector | Public |
| Country | Turkey |
| Start | 01/2019 |
| End | 12/2021 |
| Description | ICiC 4 - Griesenbach - GM-CSF gene therapy for pulmonary alveolar proteinosis |
| Amount | £74,924 (GBP) |
| Funding ID | RSRO_P62528 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 06/2018 |
| Description | ICiC 4 - Isalan - Imperial Confidence in Concept Scheme |
| Amount | £79,057 (GBP) |
| Organisation | Imperial College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 08/2019 |
| Description | ICiC 4 - Mylonas - MedCaP: MedTech Catalyst Programme |
| Amount | $1,400,000 (SGD) |
| Organisation | Agency for Science, Technology and Research (A*STAR) |
| Sector | Public |
| Country | Singapore |
| Start | 03/2020 |
| End | 10/2021 |
| Description | ICiC 4 - Shattock - Vaccines for Global Development |
| Amount | £1,999,713 (GBP) |
| Funding ID | 971617 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2020 |
| Description | ICiC 4 - Terzidou - March of Dimes Prematurity Research Center |
| Amount | £368,247 (GBP) |
| Organisation | March of Dimes Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 03/2019 |
| End | 04/2021 |
| Description | ICiC 4 - Weinberg - Project Grant |
| Amount | £177,823 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 07/2020 |
| Description | ICiC 4 - Wigneshweraraj - Leverhulme Trust - Project Grant |
| Amount | £200,000 (GBP) |
| Organisation | The Leverhulme Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 07/2021 |
| Description | ICiC 4_Zhao_Small and large molecule inhibitors of ZIP12 |
| Amount | £4,400,000 (GBP) |
| Organisation | Apollo Therapeutics |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 04/2021 |
| Description | Innovate UK Investment Accelerator |
| Amount | £149,475 (GBP) |
| Funding ID | 582222 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2018 |
| Description | Project Grant |
| Amount | £200,000 (GBP) |
| Organisation | The Leverhulme Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| Description | Research Fellowship Grant 2016 - MT |
| Amount | £56,600 (GBP) |
| Funding ID | RF16\100015 |
| Organisation | Imperial College Healthcare NHS Trust |
| Department | Imperial College Healthcare NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 07/2017 |
| Description | Research Fellowship Grant 2017 - EW |
| Amount | £50,000 (GBP) |
| Funding ID | RF17/1011 |
| Organisation | Imperial College Healthcare NHS Trust |
| Department | Imperial College Healthcare NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 07/2018 |
| Description | Research Project Grant |
| Amount | £29,500 (GBP) |
| Organisation | Genesis Research Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 07/2018 |
| Description | Ultrasound delivery of BACE1 inhibitors across the blood-brain barrier in a model of Alzheimer's disease |
| Amount | £249,203 (GBP) |
| Funding ID | ARUK-IRG2017A-7 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 10/2020 |
| Title | Isalan - ICiC 4 - ZF-HD |
| Description | Huntington's disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. It belongs to a class of rare diseases, including spinocerebral ataxias, caused by expansions of CAG-repeat sequences within genes. We have developed a gene therapy approach, based on reducing the levels of the HD gene products, while maintaining the levels of the normal proteins. By designing a zinc finger protein (transcription factor repressor) to bind expanded CAG-repeats, we were the first to demonstrate efficient mutant Huntingtin (HTT) repression in mice, with a single treatment eliminating HD clasping symptoms for several weeks (Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brains of R6/2 mice. PNAS 109: E3136-E3145, 2012). The original treatment only lasted a couple of weeks, but we have spent the last five years working on second and third generation constructs to allow sustained repression of mutant Huntingtin, in the whole brain (up to 80% lowering after AAV injection). We have recently published a new paper on this work, reporting how we can now achieve specific repression of mutant Huntingtin for a least six months (and maybe longer) after a single treatment (Agustín-Pavón et al. Mol. Neurodegeneration 11(1):64, 2016). |
| Type Of Material | Biological samples |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | This has the potential to repress the molecular cause Huntington's disease in humans with infrequent dosing and no mutagenic genome cutting (unlike other treatments in development). |
| URL | https://doi.org/10.1186/s13024-016-0128-x |
| Title | Solari - ICiC4 - Novel Protein Kinase D Inhibitors |
| Description | We have chemically synthesised a number of novel protein kinase D inhibitors attempting to enhance cellular potency by targeting a Cys residue in the active site of the kinase. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | The new compounds are still being validated and tested in biological systems. |
| Description | Blagborough - ICiC4 - Institut de Recherche en Sciences de la Santé, Burkina Faso |
| Organisation | National Center for Scientific and Technological Research (CNRST) |
| Department | Institute of Research in Health Sciences |
| Country | Burkina Faso |
| Sector | Public |
| PI Contribution | Design of and generation of materials to assess a Novel Whole-Parasite Anti-Malarial vaccine in the field. |
| Collaborator Contribution | Assessment of transmission-blocking capabilities of a Novel Whole-Parasite Anti-Malarial vaccine in the field by direct-membrane feeding assay (DMFA) on P. falciparum. |
| Impact | N/A |
| Start Year | 2016 |
| Description | Development of graphene based biosensor for exosome analysis |
| Organisation | Imperial College London |
| Department | Institute of Clinical Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Providing biologicals (antibodies, exosomes) to be tested with the biosensor. Sample preparation and electron microscopy imaging of sensors. Microfluidic devices to integrate with sensor.Prototyping to increase device usability |
| Collaborator Contribution | Graphene sensor fabrication Electronic equipment to analyse sensor output Surface analysis (XPS) |
| Impact | Multidisciplinary: Involving the field of biotechnology (microfluidic chip), physics (separation of particules using acoustic waves) and materials (use of graphene-based detection of exosomes) |
| Start Year | 2016 |
| Description | Edwards - ICiC 4 - AA |
| Organisation | Imperial College London |
| Department | Department of Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | None |
| Collaborator Contribution | Provided reagents |
| Impact | None yet |
| Start Year | 2017 |
| Description | Edwards - ICiC 4 - JS |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Dr Edwards is an expert in antibiotic resistance and leads the project at Imperial |
| Collaborator Contribution | Provided recombinant proteins, plasmids and strains |
| Impact | None yet |
| Start Year | 2017 |
| Description | Griesenbach - ICiC4 - Dr Cliff Morgan |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Expertise in pulmonary gene transfer and vector design. |
| Collaborator Contribution | Disease expert |
| Impact | N/A |
| Start Year | 2016 |
| Description | ICiC 4 - Terzidou - Bed-side miRNA analysis to predict preterm birth |
| Organisation | Imperial College London |
| Department | Department of Bioengineering |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Identified miRNA markers that can predict preterm birth/cervical shortening in high risk women which can be applied to test the paper-based assay developed by Dr Ladame. Providing biologically relevant samples for large validation using low risk population. |
| Collaborator Contribution | Development of a bed-side test based on Dr Ladame's paper-based assay to detect our identified miRNA markers. |
| Impact | https://doi.org/10.1039/C9CC05607F |
| Start Year | 2018 |
| Description | Kyrgiou - ICiC 4 - Systematic review on impact of margins |
| Organisation | European Federation For Colposcopy |
| Country | Belgium |
| Sector | Charity/Non Profit |
| PI Contribution | Scientific contribution the published paper Arbyn Lancet Oncol 2017 |
| Collaborator Contribution | Scientific contribution to the research and writing of the paper |
| Impact | M Arbyn, CWE Redman, F Verdoodt, M Kyrgiou, M Tzafettas, S Ghaem-Maghami, KU Petry, S Leeson, C Bergeron, P Nieminen, J Gondry, O Reich, EL Moss. Incomplete excision of cervical precancer as predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncology 2017 |
| Start Year | 2016 |
| Description | Porter - ICiC4 - CRUK centre collaboration |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Alexandra Porter is a member of the CRUK centre. As such she is invited to events and to apply to funding calls from the centre, including studentships, fellowships pump prime funding. She attends meetings held by the CRUK centre at which she participates in brain storming sessions to come up with new research directions. |
| Collaborator Contribution | They organise the meetings and provide funding through the centre. |
| Impact | N/A |
| Start Year | 2017 |
| Description | Wigneshweraraj - ICiC4 - Dr Luiz de Carvahlo, Crick Institute |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We conceptualised the research idea. |
| Collaborator Contribution | Provided metablome data. |
| Impact | We have obtained substantial preliminary data. |
| Start Year | 2016 |
| Description | Wigneshweraraj - ICiC4 - Prof Boris Macek, University of Tubingen |
| Organisation | Eberhard Karls University of Tübingen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | We conceptualised the research idea. |
| Collaborator Contribution | Provided proteomics data. |
| Impact | We have obtained substantial preliminary data. |
| Start Year | 2016 |
| Title | COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE |
| Description | This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma). |
| IP Reference | WO2017001812 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | N/A |
| Title | METHOD FOR PREDICTING CERVICAL SHORTENING AND PRETERM BIRTH |
| Description | The present invention provides method for predicting risk of cervical shortening, methods for predicting risk of preterm labour (PTL), and methods for characterising a pregnant subject having a history of previous PTL, mid-trimester loss or cervical cone biopsy as being in need of surveillance and/or intervention to prevent preterm labour, comprising determining the expression level of one or more of the miRNA molecules identified in Table 1 or Table 2 extracted from a biological sample obtained from said subject and comparing to a control value. Biochips and kits for use in carrying out the methods of the invention are also provided. |
| IP Reference | WO2016142688 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | N/A |
| Title | METHOD OF DETECTION |
| Description | The present invention is directed to a method for detecting the presence or absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, comprising: (a) subjecting a test sample to mass spectrometry analysis and generating a mass spectrum output; wherein said test sample comprises a bacterial membrane or a fragment thereof, wherein the fragment comprises a non- Lipid A component; (b) identifying in said mass spectrum output a first defined peak indicative of the presence of Lipid A modified by phosphoethanolamine, wherein said first defined peak is a peak present in a mass spectrum output for Lipid A modified by phosphoethanolamine and wherein said first defined peak is absent from a corresponding mass spectrum output for native Lipid A; and (c) wherein the presence of said first defined peak indicates the presence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, and wherein the absence of said first defined peak indicates the absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic. This method is also used in a screening method to identify an inhibitor of cyclic cationic polypeptide antibiotic resistance in a bacterium. The matrix solution can contain 2,5-dihydroxybenzoic acid and aids in the selective extraction, co-crystallisation and ionisation of native Lipid A and/or modified Lipid A as an integral part of a bacterial membrane. |
| IP Reference | WO2018158573 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | N/A |
| Title | NUCLEIC ACIDS, PEPTIDES AND METHODS |
| Description | Disclosed herein are novel nucleic acid molecules which encode novel polypeptides for use in treating polyglutamine diseases such as Huntington's disease. The polypeptides of the invention exhibit reduced immunotoxity in vivoand may have utility in sustained (mid-or long-term) expression in vivo. Also disclosed are methods for the treatment of polyglutamine diseases, such as Huntington's disease and the use of nucleic acids and polypeptides of the invention in medical therapy. Gene therapy methods and compositions, such as AAV vectors for use in gene therapy methods are also disclosed. |
| IP Reference | WO2017077329 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | We are developing the technology to enter clinical trials. |
| Title | PEPTIDES AND USES |
| Description | Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in mutant genes and may have applications in gene therapy. The zinc finger peptides may have nucleic acid recognition sequences according to SEQ ID NO: 101. Also disclosed are methods for constructing poly-zinc finger peptides having arrays of at least 8 zinc finger domains, along with zinc finger frameworks that may be useful for selecting zinc finger peptides from libraries. |
| IP Reference | WO2012049332 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | Commercial In Confidence |
| Impact | We are developing the technology to enter clinical trials. |
| Title | SURGICAL DEVICE AND METHODS |
| Description | A surgical device (21) comprising a deployable peripheral structure (23) for insertion into a human or animal body, and one or more surgical tools (30) disposed at least partially within the deployable peripheral structure and having a plurality of tendons (24, 25, 26, 27) connected thereto operable to manipulate the or each surgical tool. |
| IP Reference | WO2015036753 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | This is an enabling and potentially disrupting technology in the areas of minimally and ultra-minimally invasive surgery. Currently undergoing pre-clinical in vivo validation |
| Title | Blagborough - ICiC4 - A Whole-Parasite Anti-Malarial Transmission-Blocking Vaccine |
| Description | We have developed a safe, cheap, and easily cultured transgenic rodent-malaria parasite which expresses a clinically-relevant human TBV antigen on its surface in native confirmation. Vaccination with these parasites produces an immune response against the native target with no cross-reactivity, and induces a potent transmission-blocking response. We have assessed the induced efficacy with a range of adjuvants/delivery systems/regimes using a variety of assays in both the lab and the field. Efficacy is favourable compared with other clinical TBVs under development. Our principle source of funding is an Imperial CiC award. |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Impact | N/A |
| Company Name | Myricx Bio |
| Description | Myricx Bio operates a drug discovery company, focusing on cancers and viral infections where a specific protein, NMT, plays a part. |
| Year Established | 2019 |
| Impact | Myricx is led by a team of world-class scientists and drug developers with a track record of big pharma, biotech and academic successes. The Company's scientific co-founder has built a world leading platform of assay technologies resulting in the discovery and development of novel ultrapotent human NMT inhibitor classes. |
| Website | http://myricxpharma.com |
| Description | Edwards - ICiC 4 - Impfest 2016/17 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | 500 members of the public visited the 'superbugs zone' as part of Imperial festival. During this event I highlighted our work on this project. |
| Year(s) Of Engagement Activity | 2016,2017 |
| Description | Edwards - ICiC 4 - TV Interviews |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Gave TV interviews, either in the lab (ITV, Phoenix TV) or live in the studio (BBC world news) on the general issues of AMR and to highlight this project. |
| Year(s) Of Engagement Activity | 2010,2017 |
| Description | ICiC 4 - Blagborough - Cambridge Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Hundreds of individuals from a wide audience participated in evenst to learn about our research, which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas. |
| Year(s) Of Engagement Activity | 2016,2017,2018 |
| Description | ICiC 4 - Blagborough - Imperial Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Hundreds of individuals from a wide audience participated in evenst to learn about our research, which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas. |
| Year(s) Of Engagement Activity | 2016,2017,2018 |
| Description | ICiC 4 - Blagborough - event at All Party Parliamentary Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Hundreds of individuals from a wide audience participated in events to learn about our research, which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas. |
| Year(s) Of Engagement Activity | 2016,2017,2018 |
| Description | ICiC 4 - Weinberg - Presentation to entrepreneurs |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Obtaining feedback on a "pitch" from industry specialists |
| Year(s) Of Engagement Activity | 2018 |
| Description | Imperial festival 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Imperial Festival is the College's flagship annual science outreach event celebrating the best science, engineering and creativity from Imperial. With hundreds of attractions, demonstrations, interactive exhibits, talks, tours, workshops and performances put on by more than 500 exhibitors from the College's academic and student community, the 2016 Imperial Festival attracted more than 15,000 visitors to the College. The CMBL group presented some of the cutting edge bioengineering research on the topic acoustic-based microfluidic devices for early cancer diagnostics and how simple blood tests will soon replace invasive tissue biopsies for early-stage detection of certain aggressive cancers, such as pancreatic cancer. The CMBL exhibition at the Festival was a tremendous success attracting well over 600 visitors over the weekend, from the very young to the old, children, families, science enthusiasts, academics and even investors and funding bodies. The feedback we received after the event has been overwhelmingly positive. |
| Year(s) Of Engagement Activity | 2014,2016 |
| Description | Isalan - ICiC4 - Huffington Post |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was an online news article based on the paper: Agustín-Pavón C, Mielcarek M, Garriga-Canut M & Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration 11(1):64 (Sep. 2016). |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.huffingtonpost.co.uk/entry/a-single-injection-of-a-new-treatment-has-halted-progress-of-h... |
| Description | Isalan - ICiC4 - La Vanguardia |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Spanish newspaper coverage (print/online) of the paper: Agustín-Pavón C, Mielcarek M, Garriga-Canut M & Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration 11(1):64 (Sep. 2016). |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.lavanguardia.com/vida/20160920/41451928214/una-inyeccion-reduce-enfermedad-de-huntington-... |
| Description | Isalan - ICiC4 - Press release & general web blogs interest |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | After our press release our work has been picked up by many news agencies and has resulted in ongoing contacts with pharma and venture capitalists to find a route to translation. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_9-9-2016-13-13-26 |
| Description | Isalan - ICiC4 - Public Library of Science |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Online interview with PloS (Public Library of Science) which mentions this research on Huntington's disease. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://blogs.plos.org/everyone/2017/02/09/interview-with-plos-one-academic-editor-mark-isalan/ |
| Description | Isalan - ICiC4 - Research *eu magazine interview |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | They interviewed Mark Isalan regarding the paper: Agustín-Pavón C, Mielcarek M, Garriga-Canut M & Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Molecular Neurodegeneration 11(1):64 (Sep. 2016). This resulted in a print/online magazine article. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://cordis.europa.eu/news/rcn/126205_en.html |
| Description | Kedgley - ICiC 4 - Imperial Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | 400 people visited a stand at the Imperial Festival where we ran an activity stand and live experiment for people to try strength and dexterity tests and experience what how these change as people get older and develop conditions such as osteoarthritis. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Kedgley - ICiC 4 - Summer School |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | 60 students attended the Year 9 Engineering Summer School, which created interest in the different ways in which engineering could be used in medicine. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Kedgley - ICiC4 - Imperial College Human Factors Interest Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Seminar presentation by Angela Kedgley, Imperial College Human Factors Interest Group (Nov 2016). To link with other researchers and students in human factors to discuss key questions regarding how design affects patient concordance, monitoring, and compliance. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Kedgley - ICiC4 - Women@Imperial Week |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | 30 students and 2 teachers attended as part of the 2017 Demo lecture programme for schools, which has the aim of getting girls interested in Physics and Engineering. There were many questions from the students, including requests for further information about the programme, internships and careers in the field. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Kyrgiou - ICiC 4 - ESGO |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Europe's landmark meeting in Gynaecological Oncology, offers professionals a unique opportunity to learn and discuss the latest medical and scientific developments in gynaecological cancers. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://congress.esgo.org/ |
| Description | Kyrgiou - ICiC 4 - Eurogin |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | For thirty yearsThe Netherlands have been at the forefront of research on HPV and associated cancers. Among the pioneers in HPV research, the very dynamic Dutch teams have made major and continuing scientific contributions to early detection, prevention and basic research. It is also one of the first countries in the world that has implemented a comprehensive national HPV screening program. The robust scientific evidence provided by these teams confirms the cost effectiveness of risk-based screening and paves the way for the development of new strategies for the prevention of HPV-induced cancers. We are proud to highlight this scientific vitality and to pay tribute to this historic turning point which they brought. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.eurogin.com/2017/ |
| Description | Kyrgiou - ICiC 4 - Reproductive Morbidity |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Undergraduate students |
| Results and Impact | Organized by the Finnish Colposcopy Society and EFC. The Helsinki Advanced Colposcpopy Course has the BSCCP accreditation. Participants can get points for the colposcopy re-certification in UK and other countries (check the description of your national society). |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://efcolposcopy.eu/wp-content/uploads/2017/06/EFC-Nordic-Baltic-Advanced-Course-2018-advertiseme... |
| Description | Kyrgiou - ICiC 4 - The Use of Innovative Spectroscopy |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | There was great scieintific interest and exchange of ideas following each of the events |
| Year(s) Of Engagement Activity | 2018 |
| Description | Larrouy-Maumus - ICiC4 - Imperial Festival/Super Bug Zone |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | As part of the CMBI's outreach activities, we helped organising a few stands in the Superbug zone of the Imperial open to general public for awareness on AMR. |
| Year(s) Of Engagement Activity | 2015,2016 |
| Description | Levin - ICiC 4 - IEEE |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | We have had multiple talks by members of our group at educational meeting |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://iscas2017.org/ |
| Description | Mylonas - ICiC4 - B.E.S.T. Innovation Symposium (IRCAD, IhU, France) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation of our concept at the B.E.S.T. Innovation Symposium, IRCAD, IhU in Strasburg, France (Aug 2016). Industry and postgraduate students attended from around the world. Interesting discussions followed, including valuable input from the industry perspective. The novelty of the approach was acknowledged. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.best-innovation.eu/best-innovation-symposium-2016/ |
| Description | Solari - ICiC4 - Research Seminar at AstraZeneca in Mollndal, Sweden |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Roberto Solari gave a research seminar describing work conducted in his lab to the respiratory research groups at AstraZeneca in Sweden. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Tate - ICiC2 & ICiC4 - CRUK lab tours, Imperial Festival 2016 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | This event made us appreciate the importance of public engagement and we had positive feedback from attendees. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.imperial.ac.uk/festival/about/festival-2016/ |